Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12216028 | 0.90 | TUBB1 (0.44) | TUBB1TAAR1LMNAMAPK1HTT | |
| SCHEMBL8251250 | 0.87 | ACHE (0.42) | TUBB1TAAR1LMNAMAPK1HTT | |
| SCHEMBL15576975 | 0.87 | TUBB1 (0.50) | TUBB1TAAR1LMNAMAPK1HTT | |
| SCHEMBL7720468 | 0.85 | TAAR1 (0.50) | TUBB1TAAR1ACHEPOLBGAA | |
| SCHEMBL18481797 | 0.84 | LMNA (0.45) | TUBB1LMNAMAPK1HTTRAB9A | |
| SCHEMBL5354313 | 0.82 | TUBB1 (0.37) | TUBB1TAAR1LMNAMAPK1HTT | |
| Ammonia Solution, Strong SCHEMBL2235229 | 0.81 | LMNA (0.43) | TUBB1LMNAMAPK1HTTRAB9A | |
| SCHEMBL2001415 | 0.81 | LMNA (0.43) | TUBB1LMNAMAPK1HTTRAB9A | |
| SCHEMBL2937347 | 0.81 | LMNA (0.46) | TUBB1LMNAMAPK1HTTRAB9A | |
| SCHEMBL19072921 | 0.80 | TAAR1 (0.45) | TUBB1TAAR1LMNAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023102507-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023020209-A1 | UREA COMPOUND CONTAINING 2-HETEROAROMATIC RING SUBSTITUTION, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-02-23 | — | — | WO | disclosed |
| US-20210337789-A1 | Derivatives of m-Guaiacol, Their Preparation and Their Uses | UNIVERSITE DE CAEN NORMANDIE (FR) | 2021-11-04 | — | — | US | disclosed |
| EP-1720545-B1 | BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES | CHEMOCENTRYX INC (US) | 2014-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210337789-A1 | Derivatives of m-Guaiacol, Their Preparation and Their Uses | MPG, MGLL, GANC | TUBB1 2257/4885TAAR1 4214/4885LMNA 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.